Qin et al. also reported that exosomes derived from cisplatin-resistant lung cancer cells (A549/DDP) can alter other lung cancer cells’ sensitivity to cisplatin in an exosomal miR-100–5p-dependent manner with mTOR (mechanistic target of rapamycin) as its potential target [55]. Here, MTOR is linked to lung carcinoma.